Aug 14, 2025 04:03PM Macrogenics (MGNX) Misses Q2 EPS by 11c, Misses on Revenue

Jun 11, 2025 07:16AM Stifel Reiterates Hold Rating on MacroGenics (MGNX)

Jun 11, 2025 04:25AM Citizens JMP Reiterates Market Perform Rating on MacroGenics (MGNX)

Jun 10, 2025 07:07AM Macrogenics (MGNX) and Sagard Healthcare Partners Enter into ZYNYZ Royalty Purchase Agreement

May 28, 2025 04:25AM Citizens JMP shares updates on cancer treatment stocks

May 14, 2025 09:22AM MacroGenics (MGNX) PT Lowered to $5 at Stifel

May 13, 2025 04:12PM Macrogenics (MGNX) Reports In-Line Q1 EPS

Mar 25, 2025 06:48AM MacroGenics (MGNX) PT Lowered to $2 at H.C. Wainwright

Mar 21, 2025 07:48AM Stifel Reiterates Hold Rating on MacroGenics (MGNX)

Mar 21, 2025 04:39AM Citizens JMP Reiterates Market Outperform Rating on MacroGenics (MGNX)

Feb 3, 2025 04:43AM JMP Securities Biotechnology Overview

Nov 5, 2024 04:03PM Macrogenics (MGNX) Tops Q3 EPS by 69c, Beats on Revenue

Oct 30, 2024 07:30AM Macrogenics (MGNX) Announces CEO Departure

Oct 22, 2024 07:30AM Macrogenics (MGNX) Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA

Sep 18, 2024 06:42AM H.C. Wainwright Reiterates Neutral Rating on MacroGenics (MGNX)

Sep 16, 2024 08:56AM TD Cowen Reiterates Hold Rating on MacroGenics (MGNX)

Aug 21, 2024 06:44AM H.C. Wainwright Reiterates Neutral Rating on MacroGenics (MGNX)

Aug 7, 2024 10:18AM MacroGenics (MGNX) PT Lowered to $6 at Stifel

Aug 7, 2024 09:23AM MacroGenics (MGNX) PT Lowered to $5 at BMO Capital

Aug 6, 2024 04:52PM Macrogenics (MGNX) Misses Q2 EPS by 23c

Jul 31, 2024 04:18PM BTIG Downgrades MacroGenics (MGNX) to Neutral

Jul 31, 2024 03:21AM B.Riley Downgrades MacroGenics (MGNX) to Neutral

Jul 31, 2024 02:28AM Guggenheim Downgrades MacroGenics (MGNX) to Neutral

Jul 30, 2024 04:11PM Macrogenics (MGNX) Provides Vobramitamab Duocarmazine Update

Jul 30, 2024 04:01PM Macrogenics (MGNX) Achieves $100M in Milestones Related to Retifanlimab Collaboration with Incyte